Virax Biolabs Group Limited (VRAX) has a consensus analyst rating of Buy, based on 1 analyst covering the stock. Of those, 1 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for VRAX is $1.00, representing a +567.6% upside from the current price of $0.1498. Price targets range from a low of $1.00 to a high of $1.00.
